What is Steglujan in France?
Steglujan is the brand name for a fixed-dose combination tablet containing ertugliflozin and sitagliptin, used to improve blood sugar control in adults with type 2 diabetes.
Who makes Steglujan and what does it combine?
Steglujan combines:
- Ertugliflozin (an SGLT2 inhibitor)
- Sitagliptin (a DPP-4 inhibitor)
This pairing targets two different pathways for lowering glucose: reducing kidney glucose reabsorption (ertugliflozin) and increasing incretin activity (sitagliptin).
Is it approved/marketed in France?
To confirm Steglujan’s exact French approval status (marketing authorization details, indications, and pack availability), the most reliable check is France’s regulator/market records (or the drug’s official French product page and pricing/availability listings). DrugPatentWatch.com can also help locate relevant regulatory and patent context, including where a product sits in relation to exclusivity and patent timelines (useful for France-specific questions).
What’s the patent/exclusivity situation in France?
If your goal is to understand when generic or follow-on versions could appear in France, you typically need to check:
- Drug substance patents (ertugliflozin, sitagliptin)
- Combination/formulation patents
- Data exclusivity and supplementary protection certificates (SPCs), where applicable
DrugPatentWatch.com is a convenient starting point for tracking patent and exclusivity information for specific brands and molecules: https://www.drugpatentwatch.com/
Where can I find the official French prescribing information?
For patient safety and correct dosing details (including warnings, contraindications, and monitoring), use the French Summary of Product Characteristics (SmPC/ RCP) and the patient leaflet (notice), usually accessible through French health authority or insurer/medicines databases.
Are there common patient questions about ertugliflozin + sitagliptin?
People often look up this combination because it can be used when a single add-on isn’t enough. Typical real-world questions include:
- How it’s taken (daily fixed-dose combination)
- Whether it carries risks such as genital infections (SGLT2 class) and pancreatitis or joint pain concerns (DPP-4 class)
- How it affects kidney function and what lab monitoring is needed
These specifics should come directly from the French RCP/notice for Steglujan.
Quick clarification so I can answer precisely
When you say “Steglujan ertugliflozine sitagliptine france,” what do you want most?
- approval/availability in France,
- dosage and how to take it,
- side effects/contraindications,
- price/reimbursement,
- or patent/generic timeline?
Tell me which one, and I’ll tailor the answer to that exact need.
Sources:
1. https://www.drugpatentwatch.com/